Combined oral contraception as a method to maintain reproductive health


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The problem of birth control is particularly relevant in Russia where the level of induced abortion remains high, having a negative impact on women’s health. The prevalence of hormonal contraception is hampered by poor awareness about the potential benefit of hormonal agents among both women and physicians and by an inability to correctly choose among a broad range of contraceptives offered on the pharmaceutical market. Combined oral contraceptives are being continuously improved, but the emergence of new medications should not make the agents of previous generations be automatically discontinued. It should be remembered that progestins, the basis of hormonal contraception, are significantly different in the characteristics of partial effects and it is precisely these pharmacological features that determine the possibility of individually choosing a contraceptive. Gestodene-containing oral contraceptives show good tolerability and optimal menstrual cycle control, which allows them to be widely recommended as the first choice of drug in a wide female population.

Full Text

Restricted Access

About the authors

V. A Konovalov

I.P. Pavlov Ryazan State Medical University

PhD, assistant professor of obstetrics and gynecology; Ministry of Health of Russia, the chief physician of the 1st Women’s consultation.

I. V Kuznetsova

SEC Center for Women Health of the I.M. Sechenov First Moscow State Medical University

Email: ms.smith.ivk@gmail.com
MD, professor, senior researcher

References

  1. Шарапова О.В., Кулаков В.И., Стрижаков А.Н. Современные методы профилактики абортов, научно-практическая программа. М.: МЗ РФ, Международный фонд охраны здоровья матери и ребенка; 2004. [Sharapova O.V., Kulakov V.I., Strizhakov A.N. Modern methods for the prevention of abortion, scientific and practical program. M.: Ministry of Health of Russia, The International Fund for the health of mother and child; 2004. (In Russian)]
  2. Уварова Е.В. Медико-социальные аспекты репродуктивного здоровья современных девочек России. Репродуктивное здоровье детей и подростков. 2006; 4: 10-5. [Uvarova E.V. Medical and social aspects of reproductive health of modern girls of Russia. Reproduktivnoe zdorove detey i podrostkov. 2006; 4: 10-5. (In Russian)]
  3. Skouby S.O. Contraceptive use and behavior in the 21st century: a comprehensive study across five European countries. Eur. J. Contracept. Reprod. Health Care. 2010; 15(Suppl. 2): S42-53.
  4. Cibula D. Women’s contraceptive practices and sexual behaviour in Europe. Eur. J. Contracept. Reprod. Health Care 2008; 13(4): 362-75.
  5. Lopez L.M., Steiner M.J., Grimes D.A., Schulz K.F. Strategies for communicating contraceptive effectiveness. Cochrane Database Syst. Rev. 2008; (2): CD006964.
  6. United Nations Department of Economic and Social Affairs Population Division. World contraceptive use 2007. Accessed 5 August 2009 from: http://www.n.org/esa/population/ publications/contraceptive2007/contra-ceptive_2007_table.pdf
  7. Endrikat J., Gerlinger C., Richard S., Rosenbaum P., Düsterberg B. Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide. Contraception. 2011; 84(6): 549-57.
  8. Westhoff C.L., Heartwell S., Edwards S., Zieman M., Stuart G., Cwiak C. et al. Oral contraceptive discontinuation: do side effects matter? Am. J. Obstet. Gynecol. 2007; 196(4): 412. e1-6; discussion 412. e6-7.
  9. Mosher W.D., Jones J. Use of contraception in the United States: 1982-2008. Vital Health Stat. 2010; 23(29): 1-44.
  10. Gilliam M.L., Neustadt A., Kozloski M., Mistretta S., Tilmon S., Godfrey E. Adherence and acceptability of the contraceptive ring compared the pill among students: a randomized controlled trial. Obstet. Gynecol. 2010; 115: 503-10.
  11. Schindler A.E., Campagnoli C., Druckmann R., Huber J., Pasqualini J.R., Schweppe K.W., Thijssen J.H. Classification and pharmacology of progestins. Maturitas. 2008; 61(1-2): 171-80.
  12. Kulier R., Helmerhorst F.M., Maitra N., Gülmezoglu A.M. Effectiveness and acceptability of progestogens in combined oral contraceptives - a systematic review. Reprod Health. 2004; 1: 1.
  13. Stanczyk F.Z., Archer D.F. Gestodene: a review of its pharmacology, potency and tolerability in combined contraceptive preparations. Contraception. 2014; 89(4): 242-52.
  14. Höchel J., Schuett B., Ludwig M., Zurth C. Implications of different application sites on the bioavailability of a transdermal contraceptive patch containing ethinyl estradiol and gestodene: an open-label, randomized, crossover study. Int. J. Clin. Pharmacol. Ther. 2014; 52(10): 856-66.
  15. ACOG Practice Bulletin No. 110: noncontraceptive uses of hormonal contraceptives. Obstet. Gynecol. 2010; 15(1): 206-18.
  16. Wong C.L., Farquhar C., Roberts H., Proctor M. Oral contraceptive pill as treatment for primary dysmenorrhea. Cochrane Database Syst. Rev. 2009; (2): CD002120.
  17. Farquhar C., Brown J. Oral contraceptive pill for heavy menstrual bleeding. Cochrane Database Syst. Rev. 2009; (4): CD000154.
  18. Dmitrovic R., Kunselman A.R., Legro R.S. Continuous compared with cyclic oral contraceptives for the treatment of primary dysmenorrhea: a randomized controlled trial. Obstet. Gynecol. 2012; 119(6): 1143-50.
  19. Schindler A.E. Non-contraceptive benefits of oral hormonal contraceptives. Int. J. Endocrinol. Metab. 2013; 11(1): 41-7.
  20. Vessey M., Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br. J. Cancer. 2006; 95: 385-9.
  21. Lukanova A., Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol. Biomarkers Prev. 2005; 14: 98-107.
  22. Havrilesky L.J., Gierisch J.M., Moorman P.G., Coeytaux R.R., Urrutia R.P., Lowery W.J. et al. Oral contraceptive use for the primary prevention of ovarian cancer. Evid. Rep. Technol. Assess (Full Rep). 2013; 212: 1-514.
  23. Hannaford P.C., Selvaraj S., Elliot A.M., Angus V., Iversen L., Lee A. Cancer risk among users of oral contraceptive: cohort data from the Royal College of General Practitioner's oral contraceptive study. Br. Med. J. 2007; 335(7621): 651.
  24. Stegeman B.H., de Bastos M., Rosendaal F.R., van Hylckama Vlieg A., Helmerhorst F.M., Stijnen T., Dekkers O.M. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. Br. Med. J. 2013; 347: f5298.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies